Page 20 - Read Online

Page 232 Venkatesh et al. Cancer Drug Resist 2021;4:223-32 I http://dx.doi.org/10.20517/cdr.2020.84

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-63.
2. Deneka AY, Boumber Y, Beck T, Golemis EA. Tumor-targeted drug conjugates as an emerging novel therapeutic approach in small cell
lung cancer (SCLC). Cancers 2019;11:1297.
3. Srinivasarao M, Galliford CV, Low PS. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug
Discov 2015;14:203-19.
4. Srinivasarao M, Low PS. Ligand-targeted drug delivery. Chem Rev 2017;117:12133-64.
5. Ojima I. Guided molecular missiles for tumor-targeting chemotherapy - case studies using the second-generation toxoids as warheads.
Acc Chem Res 2008;41:108-19.
6. Riber CF, Smith AAA, Zelikin AN. Self-immolative linkers literally bridge disulfide chemistry and the realm of thiol-free drugs. Adv
Healthc Mater 2015;4:1887-90.
7. Lee MH, Sessler JL, Kim JS. Disulfide-based multifunctional conjugates for targeted theranostic drug delivery. Acc Chem Res
2015;48:2935-46.
8. Go Y, Jones DP. Redox compartmentalization in eukaryotic cells. Biochim Biophys Acta 2008;1780:1273-90.
9. Elkin SR, Lakoduk AM, Schmid SL. Endocytic pathways and endosomal trafficking: a primer. Wien Med wochenschr 2016;166:196-204.
10. Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem 2009;78:857-902.
11. Yang J, Chen H, Vlahov IR, Cheng J, Low PS. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET
imaging. Proc Natl Acad Sci USA 2006;103:13872-7.
12. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 2009;13:256-62.
13. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of
cancer and inflammatory diseases. Acc Chem Res 2008;41:120-9.
14. Lv Q, Yang J, Zhang R, et al. Prostate-specific membrane antigen targeted therapy of prostate cancer using a DUPA-paclitaxel conjugate.
Mol Pharm 2018;15:1842-52.
15. Leamon CP, Reddy JA, Bloomfield A, et al. Prostate-specific membrane antigen-specific antitumor activity of a self-immolative tubulysin
conjugate. Bioconjug Chem 2019;30:1805-13.
16. Kularatne SA, Wang K, Santhapuram HR, Low PS. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer
using a PSMA inhibitor as a homing ligand. Mol Pharm 2009;6:780-9.
17. Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with
177Lu-labeled PSMA-617. J Nucl Med 2016;57:1170-6.
18. Hoff DDV, Mita MM, Ramanathan RK, et al. Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients
with advanced solid tumors. Clin Cancer Res 2016;22:3157-63.
19. Giesel FL, Will L, Lawal I, et al. Intraindividual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the prospective evaluation
of patients with newly diagnosed prostate carcinoma: a pilot stud. J Nucl Med 2018;59:1076-80.
20. Kozikowski AP, Zhang J, Nan F, et al. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy
as analgesic agents. J Med Chem 2004;47:1729-38.
21. Kozikowski AP, Nan F, Conti P, et al. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II
(NAALADase). J Med Chem 2001;44:298-301.
22. Wüstemann T, Haberkorn U, Babich J, Mier W. Targeting prostate cancer: prostate-specific membrane antigen based diagnosis and
therapy. Med Res Rev 2019;39:40-69.
23. Lu Y, Parker N, Kleindl PJ, et al. Antiinflammatory activity of a novel folic acid targeted conjugate of the mTOR inhibitor everolimus.
Mol Med 2015;21:584-96.
24. Lu Y, Stinnette TW, Westrick E, Klein PJ, Gehrke MA, Cross VA. Treatment of experimental adjuvant arthritis with a novel folate
receptor-targeted folic acid-aminopterin conjugate. Arthritis Res Ther 2011;13:R56.
25. Patil Y, Shmeeda H, Amitay Y, Ohana P, Kumar S, Gabizon A. Targeting of folate-conjugated liposomes with co-entrapped drugs to
prostate cancer cells via prostate-specific membrane antigen (PSMA). Nanomedicine 2018;14:1407-16.
26. Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer
Res 1998;58:4055-60.